Trastuzumab is a therapeutic humanised monoclonal antibody targeting the Her2 receptor tyrosine kinase. Her2 is over-expressed,duetogeneamplification,inapproximately30%ofbreastcancersandconfersaworseprognosis.Trastuzumabhas beenusedclinicallyforoveradecadeandisnowusedroutinelyinthetreatmentofHer2-positivebreastcancerinthemetastaticand adjuvantsetting.Itsmechanismsofactionandresistance,aswellasitspharmacokineticsandefficacyindifferentclinicalscenarioshave beenexploredandincreasinglyclarifiedduringitspre-marketingandpost-marketingdevelopment.Nonetheless,numerousscientific andclinicalissuesremainnotfullyelucidated.Thisreviewdiscussesthepharmacodynamicandpharmacokineticpropertiesoftrastuzumabanditscurrentuseinthetreatmentofbreastcancer.
Introduction
Trastuzumab is a humanised monoclonal antibody (mAB) used therapeutically in the treatment of EpidermalGrowthFactorReceptor2(ErbB2,Her2, Neu) positive breast cancer. The efficacious use of antibodies in the treatment of cancer has been a goal of biologists for over 100 years. 1 That it has recentlycometofruitionisduetonumeroustechnical advancesoverthelast40years,notleastthedevelopmentofmonoclonalantibodytechnology.Inthe1970s KholerandMilsteindevelopedaprocesswherebythe fusion of antigen-exposed mouse spleen cells with mousemyelomacells,followedbyclonalselection, generated unlimited supplies of highly specific and clonally-derived antibodies. 2 They immediately recognised and commented on the therapeutic potential of this technology. However, substantial barriers to theclinicalexploitationofmABsremained,notleast immunogenicity of murine antibodies in humans. 3 Subsequent developments, using the nascent recombinantDNAtechnologyofthe1970sand80s,sawthe splicingofhumanandrodentantibodysequences 4,5 to thepointwherehypervariableregionsofhumanlight and heavy immunoglobulin (Ig) chains could be substituted with antigen specific hypervariable regions ofrodentoriginpriortotransfectionintomelanoma cell lines and clonal selection. 6 Atthetimeofwriting there are 31 FDA-approved monoclonal antibodies, 12ofwhichareusedinoncology,eithertherapeuticallyorforimaging. 7 The period between the end of the last century and the beginning of the current one has seen great improvementsinthemanagementofbreastcancer,to the extent that an increased incidence in Europe has been accompanied by a decrease in mortality. 8 The decrease in mortality is attributable to the introductionofscreeningprogramsinanumberofnationsand improvements in therapy resulting from improved understanding of the molecular etiology of the disease. However,breastcanceristhemostcommonly occurringcancerinwomen,remainsthesecondmost commoncauseofdeathfromcanceroverallandisthe mostcommoncauseofdeathfromcancerinwomen agedbetween20and59. 9 It is a heterogeneous disease andelementsofthisheterogeneityhavebeenexploited to develop therapeutic options. For example~70% of breast cancers are estrogen and/or progesterone receptor positive. Many of these tumours are dependentonestradiolforsurvivalandproliferation, and thereforesusceptibletoinhibitionofproliferation by small molecule estrogen signalling antagonists.
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Her2isover-expressed,duetogeneamplification,in approximately 25% to 30% of breast cancers and is associated,intheabsenceoftargetedtherapy,witha poorer prognosis than Her2-negative tumours.
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A185 kDa receptor tyrosine kinase (RTK), Her2 in common with other RTKs has an extracellular domain, a transmembrane domain and a cytoplasmic kinase domain. 12, 13 IncontrasttootherRTKsnoextracellular ligand for Her2 has been demonstrated. Despite thelackofidentifiedligand,Her2isstillcapableof mediatingintracellularproliferativeandpro-survival signallingviaheterodimerisationwithothermembers oftheErbBfamilyofreceptorsandisbelievedtobe thepreferredbindingpartnerofEGFR(Her1),Her3 and Her4. 14, 15 This may be of particular importance for the facilitation of ligand driven Her3 signalling, asHer3haslimitedintrinsictyrosinekinaseactivity and requires the activity supplied by the heterodimeric partner. 16, 17 Of the potential combinations of ErbB dimers the Her2/Her3 heterodimer is believed to be the main oncogenic dimer. 18 It has also been hypothesised that ligand-independent homodimerisation is sufficient to drive proliferative signalling. 19 This review will discuss the metabolism and pharmacologyoftrastuzumabandtheuseof trastuzumabinthe clinic.
Metabolism
Thestudyofthecatabolismoftherapeuticantibodies presents a challenge to pharmacologists. Generically thedegradativemetabolismofsmallmoleculedrugs canbecategorisedasaprocessofenzymatictransformation of a compound to more hydrophilic product (Phase I), more amenable to direct excretion or conjugationwithanendogenousmolecule(PhaseII)priorto excretion. 20 Themetabolismofsmallmoleculedrugs predominantly, but not exclusively, occurs in the liver andexcretiongenerallyoccursviaurineandfaeces. Therapeutic proteins generally, and therapeutic antibodiesspecifically,arenottypicallysubstratesforthe characterisedenzymesofdrugmetabolism.Whilethe mechanismoftrastuzumabmetabolismhasnotbeen extensively studied, it is assumed that the pathway ofdegradationaccuratelyreflectsthatofendogenous IgGantibodies,theendpointofcatabolismbeingthe releaseoftheconstituentaminoacidsbyintracellular proteolytic degradation.The mechanisms that influence the metabolism of antibodies can be classified into three broad categories (Fig.1) .
FcγR
TheFcγRs-mayhavearoleintheclearanceofantibodies, 21 but they also serve as the bridge between theAb:Ag interaction and the effector mechanisms of the Ab-mediated immune response. By analogy, theFcγRmoleculesareessentialforsomeofthepro-posedmechanismsofactionoftrastuzumabandwill bediscussedinthecontextofpharmacodynamics.
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FcRn
In the mid 1960s two apparently disparate observationsofthebehaviourofIgGin vivowereelegantly synthesised to generate a readily testable hypothesis.
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Theseobservationswere:
• ThatingestedmaternalIgGwastransmittedacross theintestinalepitheliumofneonatalmicebypinocytosis and that this transmission was saturable, with functional antibody re-entering the circulation or being degraded in the epithelium.
• ThattherateofIgGcatabolismincreasedinproportion to concentration.
Brambell and colleagues postulated that both phenomena could readily be explained by the presence of a receptor that protected IgG from proteolysis in lysosomes.This receptor, termed FcRn for neonatal Fc receptor, was initially identified in the intestine of neonatal rats 24 and subsequently in the syncytiotrophoblastsofhumans 25 and is the receptor that mediates the transfer of IgG from maternal to infant circulation in rats and humans respectively. StructurallytheFcRnisamembraneboundheterodimercomprisedofanalphachain,whichisamember of the MHC class I family, and a β2 microglobulin chain (β2M). 24 ThattheFcRnisalsotheIgGprotective receptor postulated in the Brambell hypothesis has beendemonstrateddefinitively,atleastinmice,ingene knockoutexperiments.Micedeficientineitherβ2M ortheFcRnalphachainhavebothalowerconcentrationofendogenousIgGandamorerapidclearanceof radio-labelled IgG. [26] [27] [28] [29] [30] Inhumans,FcRnisexpressed in placenta, heart, lung, liver, kidney, pancreas, breast, endothelial cells and dendritic cells. 25, [31] [32] [33] TheFcportion of antibodies interacts with the FcRn receptor at pH6, but not at physiological pH 25 and it is likely thatplasmaIgGistakenintoendothelialcellsbyfluid phase endocytosis rather than receptor-mediated transfer.OnceintheearlyendosometheFcRnboundIgG isprotectedfromthelysosomalproteolysisandmay potentially be transferred into the tissue or returned tothecirculation.Whiletheformerscenariohasnot been disproved the latter has been demonstrated in a Tie 2 Cre/Lox mouse model engineered to have no expression of the FcRn alpha chain in endothelial or haematopoietic cells. 30 Phenotypically this mouse modelresemblesboththeFcRnandβ2M knock-out micewithalowerconcentrationofendogenousIgG andincreasedrateofclearanceofhumanIgG,indicatingthattheexpressionofFcRninthesetissuesalone issufficienttomaintainthestabilityofIgGinblood. 30 WhetherFcRnfunctionspredominantlyasastabiliser rather than a transporter in all other adult tissues is notknown.ItishypothesisedthatexpressionofFcRn in the proximal tubular cells of the kidney contributes to re-absorption of IgG from the urine 31 and it has been observed that IgG concentrations in the bile areverylowdespitethepresenceofFcRnexpression on hepatocytes, 34 bothphenomenathatwillresultin reducedplasmaIgGclearance.WhileFcRnfunction increasesthestabilityofIgGandisthesaturablemoleculethatresultsinnonlinearclearanceofIgGathigh concentrations, it is not envisaged that endothelial FcRnexpressionwillinfluencethebloodconcentration oftrastuzumab,whichatmaximummeasuredconcentrationsis~5%oftheIgGserumconcentration,andat steadystateis~0.5%. 35, 36 However,itisofinterestthat FcRnisexpressedinnormalbreastandbreasttumour tissue, 33 andmayprotectlocalconcentrationsofdrug at the intended target.While FcRn should not influencethebloodconcentrationoftrastuzumabattherapeutic concentrations, under physiological conditions it is worth noting that high-dose corticosteroids do resultinincreasedcatabolismofIgGinbothmiceand humans 37, 38 and it has been demonstrated that corticosteroidsleadtoadecreaseinFcRnexpression. 39 
Antigen-mediated catabolism
The interactions of antibody with antigen can influence the catabolism of antibodies, both by receptor-mediated endocytosis and the endocytosis of immune complexes following interaction of the antibody with solubleAg. 21, 40 This process will be saturable and may contribute to a non linear aspect of the pharmacokinetics of trastuzumab at low concentrations. 41, 42 However,incontrasttotherelationship between FcRn and IgG, the phenomenon of generic Ab:Ag-mediated catabolism cannot be extrapolated to the influence of membrane or solubleHer2onthecatabolismoftrastuzumab.While the interaction between trastuzumab and the Her2 antigenmayinfluencecatabolism,itisalsoessential forthepharmacodynamicsoftrastuzumabandwill bediscussedbelow.
Pharmacokinetics
Trastuzumab is currently administered clinically as a 90 minute IV infusion of a 4 mg/kg loading dose followed by 2 mg/kg every week, or by a three weekly regimen of 8 mg/kg as a loading dose followed by 6 mg/kg every three weeks.A population PKanalysisofdatafrom476patientsextractedfrom previousstudies,themajorityofwhomweretreated with the weekly regimen, revealed a two compartmentlinearmodelasthemostappropriatefitofthe data. The model predicted a steady-state trough concentration of 66 µg/ml with clearance of 0.225 l/d, volumeofdistribution(Vd)of2.95landaterminal half-life (t½) of 28.5 days. 43 This compares with a t½of23daysforendogenousIgGandtheVdcorre-spondstoplasmavolume.Highlevelsofcirculating Her2extracellulardomain(ECD),morethan4sites of metastases and high body weight were all associated with a lower predicted plasma concentration. While these covariates were statistically significant themagnitudeoftheeffectwassmallcomparedtothe overallvariabilityofexposureandtheyareunlikely tobeofclinicalorpredictivebenefit. 43 The estimated steady-state trough concentration is comparable to thatseeninthethreeweeklyschedule. 36, 44, 45 ThepopulationPKanalysiswasincontrasttoearlier observations. Although the three initial phase one studies of trastuzumab have not been published in extenso, the available data show that half-life tended toincreasewithincreasingdose,fromapproximately 1 day in the lowest dose group (10 mg) to 2 weeks in the highest dose group (500 mg). 46 Early phase II studies with a PK element reported a mean half life ofbetween1.1and11days,withahighlevelofECD beingassociatedwithashorterhalflifeandlowertrough concentration. 41, 47, 48 Thefirstpublishedstudyusingthe weeklyweight-adjustedregimen 48 reported PK parametersthat,otherthanthemeant½ value of 6.5days, were consistent with the subsequent population PK model 43 withVdof2.7litresandameantroughcon-centrationatsteadystateofapproximately70µg/ml. The first dose escalation study of trastuzumab to be published included concentration-time curves over a threeweekperiodfrompatientsadministered1,2,4 or8mg/kg.Thedoseconcentration-timecurveatthe highest dose appeared to show biphasic elimination withafastinitialdecreaseintrastuzumabconcentrationover4daysfollowedbyaslowerdecreaseover the subsequent 11 days. Mean estimates of half life wereshortcomparedtothose predictedfromthetwo compartment linear model developed by Bruno et al, rangingfrom2.7daysfollowing1mg/kgto10.4days followingadministrationofthe8mg/kgdose.Asimilar non-linear mechanism was seen, with clearance whichdecreasedwithincreasingdose,suggestingthat thepharmacokineticsoftrastuzumabwerenon-linear and saturable at clinically relevant doses. 42 However, whenplottedagainstdosetheclearanceandt½values appearedtoplateauat4mg/kg,indicatingtrastuzumab pharmacokinetics are linear and non-saturated at higher doses,suggestingthattwodistinctmechanismsofdistributionoreliminationinfluenceclearance.
The initial assumption that trastuzumab pharmacokinetics were non-linear and the observation that accumulation can occur for up to 32 weeks before steady-state is reached, led to the hypothesis that a longerdurationdosingschedule,moreconvenientforthe patient,couldbeadministeredwithoutloweringexposure to the drug. The three-weekly schedule results inahigherpeakandlowertroughconcentrationthan seenwiththeweeklyschedule,butoverallexposure todrugandefficacyarecomparable. 36, 44 Theeffectivenessofthethree-weeklyscheduleismorelikelytobe duetothet½of28.5daysthannon-linearPK.
There are no apparent pharmacokinetic drug interactionsbetweentrastuzumabandcyclophosphamide, cisplatin, gemcitibine, paclitaxel or lapatinib. 43, 44, 46, [49] [50] [51] With regard to the potential interaction with other monoclonalantibodies,aphaseItrialoftrastuzumab in combination with the anti-Vascular Endothelial Growth Factor (VEGF) monoclonal antibody bevacizumab reported that the pharmacokinetics of eitheragentwereunalteredbyco-administration.
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Mechanism of Action
Themechanismbywhichtrastuzumabexertsananti tumour activity is complex and likely to be multifactorial. The question of the clinical relevance of proposedmechanismsofactionisalsocomplicated by differences in the response of tumour cells to trastuzumab in vivo and in vitro.Forexample,while trastuzumab-induced apoptosis has been observed in clinical tissue and xenografts, 53, 54 it is not commonly observed in tissue culture models. All proposed mechanisms are predicated on the interaction ofthecomplementarydeterminingregion(CDR)of theantibodywiththeantigen,andthedevelopment oftrastuzumabasanantibodyspecifically targeting Her2 can be viewed as a success. However, the complexity of trastuzumab's mechanism of action lies in the downstream consequences of theAb:Ag interaction, and can be categorised as those that are immunologically mediated and those that are antagonisticofsignallingpathways.
immunological mechanisms
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immunological process whereby the cytolytic activity of a subset of lymphocytes, natural killer (NK)cells,istargetedtothedestructionofhosttissues bytarget-specificantibodies (Fig. 2) . The process is 
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TheroleofADCCintheefficacy oftrastuzumabwasfirstsuggestedin vitroaspartof theinitialcharacterisationofthedrug 56 and has been subsequently demonstrated in murine models, ex vivo and in clinical samples. For example, trastuzumab prevents the growth of Her2-positive BT474M1 explants in wildtype nude mice, but this inhibition isabrogatedinFcγR -/-animalsofthesamebackground.
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Administration of trastuzumab enhances ex vivo ADCC activity in the neoadjuvant 58, 59 and metastatic setting 60 and the induction of ADCC is associated with improved response. An increase in tumour-associatedNKcellshasalsobeenobservedin Her2-positive primary breast tumours in trastuzumab treatedpatientscomparedtocontrolsnottreatedwith trastuzumab. 22 The FcγRIIIa gene contains a single nucleotide polymorphism that results in a substitution ofavalineforaphenylalanineatresidue158.There are suggestions that breast cancer patients who are homozygousforthevalinegenotypehaveincreased ADCC activity and prolonged progression free survivalwhentreatedwithtrastuzumab. 59, 61 Theclinicalrelevanceofotherantibody mediated immuneeffectormechanismsisuncertain.Lowaffinityanti-Her2CD8+Tcellshavebeenidentifiedand can be clonally expanded ex-vivo. There is in vitro evidence that trastuzumab enhances the cytolytic activity of these cells, via internalisation of Her2 and increased expression of Her2 epitopes in the contextofClassIMHC,buttheclinicalsignificance ofthisisunknown. 62 It has also been demonstrated that while trastuzumab can recruit complement to theHer2-positivecellsurfacethishasnoeffecton cell death.
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Cell signalling mechanisms
ThegrowthofHer2-positivecellsisinhibitedin vitro bytrastuzumabandthisgrowthinhibitionisconcomitantwithinhibitionofthepro-survivalandproliferativePI3K/AKTandMAPKsignallingpathways.
64-66
Ofthesetwopathways,in vitro data suggest that the PI3 K/AKT axis is the most important. It has been demonstrated that introduction of constitutiveAKT activity by transfection is sufficient to abrogate trastuzumab-mediatedgrowthinhibition, 67 cell-cycle arrest and differential gene expression. 68 There is also evidence that functional PTEN, a phosphatase that antagonises PI3 K signalling, is essential for trastuzumab-mediated growth inhibition. 69, 70 The lack of trastuzumab-induced apoptosis in cell line modelsissurprisinginlightoftheobservedinhibitionofPI3Ksignalling.Incontrast,increasedlevels ofapoptosisareobservedinclinicaltumoursamples from patients treated with trastuzumab, but paradoxicallythisincreaseisseenwithoutanincreasein AKT phosphorylation in the same samples.
53 Another studyhasrevealedanassociationbetweenpoorsurvival outcome in patients treated with trastuzumab andapotentialhighPI3Kactivityphenotype,characterisedbylowPTENexpressionorPI3Kmutation conferringconstitutiveactivation. 70 
Anti-angiogenesis
Angiogenesis is the formation of new blood vasculature in response to low oxygen tension or angiogenicsignallingpathways.Itisconsideredahallmark of cancer and is necessary for the growth of solid tumours beyond the size dictated by the diffusion of oxygen through the tissue. 71 Both low oxygen andthePI3K/AKTsignallingpathwaycan mediate an increase in the activity of the Hypoxia Inducible Factor-1transcriptionfactorandthesubsequent inductionanddown-regulationofproandantiangiogenic factors respectively. 72, 73 These include VEGF whichisapotentinducerofendothelialproliferation, and the anti angiogenic factor thrombospondin-1. Her2expressionhasbeenshowntobecorrelatedwith VEGFexpressioninbreasttumours. 74 This association appearstobemediatedviathePI3K/AKTsignalling pathway 74, 75 andinductionofVEGFcanbeabrogated by trastuzumab in vitro. 76 Treatmentwithtrastuzumab ofmicebearingestablishedtumoursfromxenografts of Her2-positive cells results in normalisation and decreaseddensityoftumourvasculature. 77 
inhibition of Her2 shedding
Her2 is cleaved by a metalloproteinase, ADAM10, to yield the released extra-cellular domain found in plasmaanda95kDafragmentthatisthemembrane-bound internal kinase domain. 78, 79 In the pre-trastuzumab era expression of the p95 fragment was associated withpoorprognosis. 80 Trastuzumab inhibits the cleavageofHer2inSKBR3andBT-474cellsin vitro.
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Early Clinical Studies
The early clinical development of trastuzumab, unlike the vast majority of anti-cancer agents, has beencharacterizedbytheexclusivefocusonaparticular subset of patients, i.e. the Her2-positive breast cancer patients. Since the first three phase I trials, patients have been pre-selected on the basis ofHer2expressionintumours.Intheseinitialstudiestheauthorsfailedtoreachamaximumtolerated dose(doserangefrom10to500mgIVweekly)and noneofthefourreportedseriousadverseeventswas considered to be related to trastuzumab treatment. 46 FoursubsequentphaseIItrialsevaluatedtheactivity ofweeklyadministration,bothasmonotherapyand incombination.Inparticular,afirststudyoftrastuzumabgivenassingle-agentataflatdoseof100mg weekly with a loading dose of 250 mg showed an overallresponserate(ORR)of11.6%in46patients withpre-treated(medianof2priorregimens)metastatic tumours expressing Her2 in more than 25% ofcells(morethan50%ofcellsin85%ofcases). 36 A second combination study of trastuzumab (same schedule as above) and cisplatin (75 mg/m 2 every 28 days) showed an interesting ORR of 24% in a seriesof37heavilypre-treatedpatients.Inthistrial tumours were required to have evidence of overexpression (2+ or 3+) of Her2 as determined by immuno-histochemistry. 41 A third, much larger, multicentretrialevaluatedtheactivityofasingle-agent, weight-basedweeklyregimen(loadingdose4mg/kg followedby2mg/kg)in222pre-treatedpatients.The ORRassessedbyanindependentresponseevaluation committeewas15%intheintent-to-treatpopulation andthemostclinicallysignificantadverseeventwas cardiac dysfunction, occurring in 4.7% of cases. 48 Finally, a randomized trial conducted in previously untreated patients demonstrated the equivalence in termsofactivityandsafetyoftwodifferentweekly schedules(2mg/kgor4mg/kg).Mostinterestingly, aretrospectivecorrelativeanalysisofHer2geneampli-fication by fluorescent in situ hybridization (FISH) showedthatobjectiveremissions(26%)werealmost entirelyconfinedtoFISH-amplifiedcases:ORRwas infact34%in79FISH-positivecasesandonly7% in 29 FISH-negative patients. 82 Taken together, the resultsoftheseinitialclinicalstudiespromptedthe manufacturer and the researchers to broaden their evaluationwithincontrolledsettings.
Efficacy
Metastatic setting
In2001apivotalrandomizedphaseIIItrial provided evidence of trastuzumab efficacy in combination with chemotherapy in patients with previously untreated, Her2-positive, metastatic breast cancer. Concomitantly with these large controlled trials two important phase II studies showed that a three-weekly schedule (8 mg/kg loading dose followedby6mg/kg),incombinationwithpaclitaxelor asmonotherapy,wasabletoachievethesameresults in terms of response rates and plasma trough levels as the standard weekly regimen. 36, 44 Beside the taxanes, other chemotherapeutic agents, such as vinorelbine, capecitabine and carboplatin have been tested in combination with trastuzumab in various nonrandomized and randomized trials. The combination withvinorelbine,inparticular,hasbeencomparedin asmallrandomizedphaseIItrialwithaweeklyregimenoftrastuzumabplusataxane(eitherpaclitaxelor docetaxel)andtheresultsofthiscomparisonrevealed equivalence between the two arms in terms of efficacyandsafety. 85 A recent review of a large mono-institutional cohort of patients has shown that, despite the well-documented negative prognostic influence of Her2 over-expression, Her2-positive metastatic breast cancer patients treated with trastuzumab can achieve a better overall outcome than Her2-negative patients.
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Adjuvant setting
WhenusedasadjuvanttreatmentforearlystageHer2-positive breast cancers, trastuzumab has been consistentlydemonstratedtoreducetheriskofrecurrence by 30 to 50%. Table 1 shows the major findings of fourlargeandtwosmallerrandomizedtrialsinterms ofefficacyandtoxicity,alongwithsomenotabledifferenceswithregardtovariousaspects,includingthe sizeofpatientpopulation,durationoftreatment,type of associated adjuvant chemotherapy, trastuzumab scheduleandtimingofadministration.
In particular, the large HERA trial 87-89 adopted a rather pragmatic approach, encompassing a wide range of adjuvant chemotherapy regimens in its inclusioncriteria.Thisfeaturemakesthestudyhighly representativeofclinicalpracticeandconfersawide applicability to the results. Trastuzumab every three weekswasadministeredforoneyearafterthecompletion of chemotherapy in this setting and a third randomization arm (data not released yet) evaluated a two-yeartreatmentduration.TheNSABPB-31andthe NCCTG-N9831trials 90,91 reflectthepopularityofthe AC → P schedule (Doxorubicin/Cyclophosphamide followed by Paclitaxel). They both focused on the concomitantadministrationofpaclitaxelandweekly trastuzumab,whichhadbeenshowntobesynergistic, buttheNCCTG-N9831researchersalsoconsidereda comparisonwithasequentialarm.TheBCIRG006 study 92, 93 aimed to specifically evaluate the efficacy oftrastuzumabinassociationwithananthracyclinefreeregimen(Docetaxel/Carboplatin)orwithamore standard regimen (Doxorubicin/Cyclophosphamide followedbyDocetaxel).
As can be seen from a cross-comparison of the efficacy results reported in Table 1 , the concomitant administration of trastuzumab (NSABP B-31/ NCCTG-N9831jointanalysisandBCIRG006)with chemotherapyseemstoconferaslightlylargerbenefitintermsofefficacy,comparedwiththesequential administration, although these data could be biased by differentdurationsoffollow-upanddifferentratesof treatment cross-over among the studies. On the other hand, incidence of cardiotoxicity appears slightly higherinthetrialsofconcomitanttrastuzumab. It is noteworthy that a recent medium-sized study of adjuvant trastuzumab failed to demonstrateaclearadvantageindisease-freesurvivaland overall survival. 96 Theauthorsidentifiedapotential explanationforthisresultintheratherhighrateof treatment discontinuation, mainly due to cardiac toxicity.
Neo-adjuvant setting
Many non-randomized studies have demonstrated the extreme activity of trastuzumab in association with chemotherapy in the pre-operative setting.
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A very promising randomized phase II trial confirmed the efficacy of this approach, 100 achieving an unprecedented rate of pathological Complete Remissions (pCR) (66.7% for chemotherapy plus trastuzumab versus 25% for chemotherapy alone) inalimitedseriesofpatientswithoperableprimary breastcancer.Recently,alargerandomizedphaseIII trial has evaluated the combination of trastuzumab with a poly-chemotherapy regimen in the setting oflocally-advancedbreastcancer,achievingabenefit in terms of pCR rate and a substantial prolongation in event-free survival, with an acceptable cardiacsafety. 101 Inthisstudy,whichincludednoninflammatoryT4,inflammatoryandN2oripsilateral tumours,trastuzumabwasadministeredbothpre-operatively(inassociationwithdoxorubicin,paclitaxel and cyclophosphamide/methotrexate/fluorouracil) andpost-operatively,tocompleteoneyearoftreatment.Importantly,19%ofpatientsinthecontrolarm crossedovertoadjuvanttrastuzumabaftertheresults of the major randomized trials became available. DespitetheexcitingresultsintermsofpCRsmany clinical questions, including choice of chemotherapeutic drugs, combination with anthracyclines and duration of treatment, remain unsolved and use of pre-operative trastuzumab in clinical practice is still notwidelyestablished. Abbreviations: Ch, any chemotherapy; A, adriamycin; C, cyclophosphamide; H, herceptin; P, paclitaxel; T, docetaxel; Ca, carboplatin; F, fluorouracil; e, epirubicin; v, vinorelbine; w, weekly; 3w, 3-weekly; NR, not reported; LveF, left ventricle ejection fraction; DFS, Disease Free Survival; HR, Hazard Ratio; OS, Overall Survival; DDFS, Distant Disease-Free Survival; Cross-Over, Proportion of patients in the observation arm who crossed-over to the trastuzumab arm after 1st release of efficacy data. Note: *significant LVEF drop, **LVEF drop . 10%, ***LveF drop . 20%, ****LveF  45% and/or 45%-49% + 15% decrease.
Predictors of efficacy
Trastuzumab was originally developed and is routinely used only in Her2 over-expressing and/or amplifiedbreasttumoursandtheimplementationof the recent American Society of Clinical Oncology/ CollegeofAmericanPathologistsguidelinesonHer2 testing is contributing to improve patient selection forthistargetedtreatment. 102 A retrospective analysis ofSlamon'spivotalphaseIIItrialoftrastuzumabin advancedpatientsconfirmedthatthebenefitwaslimited to patients with Her2-amplified tumours. 83, 103 A recent exploratory analysis from the NSABP group suggestedthattheadvantageofadjuvanttrastuzumab may not be limited to Her2-positive cases, 104 but it must be highlighted that these results emerge from a central re-testing of samples that were considered Her2-positive in peripheral laboratories. Many randomized trials have been retrospectively evaluated for the potential role of estrogen receptor (ER) and progesterone receptor (PR) expression in trastuzumabefficacy.Allreportsconsistentlyshowthatthe benefitderivedfromuseoftrastuzumabissimilarin hormone-receptor positive and in hormone-receptor negative patients, in advanced, 105 adjuvant 87,90 and neo-adjuvant setting. 101, 106 Likewise,theco-expression of EGFR and Her2, evaluatedin a limitedseries of advanced patients, does not seem to predict any additional effect. 107 Other biologic markers potentially implicatedinresponsetotherapywillbediscussedin thecontextoftrastuzumabresistance.
Safety
Trastuzumabisgenerallywelltoleratedandthemost frequentacuteadverseeventisahypersensitivity-like infusionreaction. 108 However,theoccurrenceofcardiacdysfunctioncanbeamajorconcerninaminority ofpatientsanddefinitivetrastuzumabdiscontinuation following cardiotoxicity might favour recurrence or progressionofthedisease. Thepotentialmechanismsofthissignificantside effecthavebeenstudiedrecently.Thereisabundant laboratory evidence that Her2 has an important role incardiomyocytedevelopmentandfunction.Her2in factfunctionsasaco-receptorforHer3andHer4and their peptide ligands, the neuregulins, all of which areexpressedincardiactissue.Accordingtooneof themostacceptedmodels,theinhibitionofHer2sig-nalling leads to mitochondrial dysfunction andATP depletionand,inturn,toreducedcontractilityofthe cardiomyocyte.
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Clinically,trastuzumab-relatedcardiotoxicitycan spanarangeofvariousclinicalsituations,fromasymptomatic variations in the heart contractility (measured as Left Ventricular Ejection Fraction-LVEF) to severe and sometimes fatal cardiac failure, and has somepeculiarfeaturessuchastheabsenceofultrastructural changes in the heart muscle and a general tendency to reversibility.
In the pivotal registration trial, 83 congestive heart failure(CHF)wasreportedinanunexpectedlyhigh proportion of patient: its incidence in the paclitaxel plus trastuzumab and the anthracycline plus trastuzumab arms was respectively 13% and 27%. In the four large adjuvant trials, 89, 91, 93, 111 where cardiac eligibility criteria were stringent and trastuzumab was interrupted or discontinued in response to the developmentofcardiacdysfunction,theincidenceofgrade III-IVCHFrangedfrom0.4to3.8%(Table1).Exhaustiveanalysesofclinicaldatainboththeadvancedand earlysettingshaveshownthatolderage,pre-existing cardiacdiseasesorriskfactorsanduseofanthracyclinescanallcontributetoanincreasedlikelihoodof developing trastuzumab-related cardiotoxicity.
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In clinical practice, a widely accepted approach to minimize this potentially life-threatening sideeffect includes a baseline assessment of LVEF followed by regular on-treatment monitoring, possible interruption/discontinuation of trastuzumab and the introduction of appropriate cardiac medication (e.g. Angiotensin-ConvertingEnzymeInhibitors).
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Controversial Clinical Issues Monotherapy or combination
Trastuzumab has been shown to be effective both as a single agent and in combination with chemotherapy.Inordertodefinethebesttreatmentstrategy,twosimilarrandomizedstudieshaverecently compared a 'sequential' therapy with the combination of trastuzumab plus docetaxel as first-line treatment in two series of patients with advanced breast cancer. 114, 115 In the first trial the sequential arm consisted of trastuzumab three-weekly, followedbydocetaxelalone(100mg/m 2 ) at progression,whereasinthelattertrastuzumabmonotherapy was given weekly and docetaxel (60 mg/m 2 ) was introduced at progression without suspending the antibody. It should be noted that in the first paper thevastmajorityofpatientshadvisceralmetastases andinthesecondtrialpatientswithonlybonydiseasewereexcludedfromthetrial.Intermsofsafety, no substantial difference emerged between the sequence and the combination, whereas ORR and progression-free survival (PFS) were substantially higher in the combination arm compared to the monotherapy stage of the sequential arm in both studies. The subsequent introduction of docetaxel didnotseemtocompletelyfillthegapintermsof efficacy,sincethehazardratioforoverallsurvival (OS)was2.72(P =0.04)infavourofthecombination in Inoue's work 115 and median OS were 20.2 monthsinthesequentialarmand30.5monthsfor the combination in Bontenbal's trial, 114 although this difference did not achieve statistical significance.Takentogether,theseresultsseemtofavour thecombinationregimen,atleastinthissubsetof advancedpatientswithmostlyvisceraldisease.
Combination with hormone treatments
A recent study has shown that the addition of trastuzumab to anastrozole in the treatment of metastaticpatientswithbothHer2-positiveandHormone Receptor-positive tumours confers a significant benefitintermsofORR(6.8%vs.20.3%)andPFS (2.4 months vs. 4.8 months), without an evident impactonsafety. 116 As a result, the European MedicinesAgencyapprovedtheuseofthecombinationof trastuzumab with an aromatase inhibitor in this setting. Although many oncologists argue that a traditionalcombinationoftrastuzumabandchemotherapy wouldbettercontrolthissubsetoftumours,thehormonal/trastuzumab approach could be useful where chemotherapyisnotfeasibleorinpatientswithminimal bony metastatic disease, in order to delay the introductionoftraditionalcytotoxicdrugs.
Combination with anthracyclines
Thecombinationoftrastuzumabwithdoxorubicinwas initiallyfoundtocauseanunacceptablerateofheart failure 83 andwasneverintroducedinclinicalpractice, although its synergism was proved in 'in vitro' and clinicalstudies.Inordertoovercomethisdrawback, many authors have evaluated the use of alternative, less cardiotoxic anthracyclines. In particular, liposomal doxorubicin, both in the pegylated and in the non-pegylatedform,hasbeenshowntobeactiveand relativelysafeinassociationwithtrastuzumabinseveral phase II studies.
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Ontheotherhand,conflictingresultshavebeenreportedwithregardtocardiac safetyoftrastuzumabplusepirubicin. 120, 121 Although promising early evaluations have been reported, the simultaneoususeofanthracyclinesandtrastuzumab is currently limited to clinical trials.
Trastuzumab and CNS metastases
Her2-positive breast cancer patients have a higher riskofdevelopingmetastasestothecentralnervous system (CNS) and treatment with trastuzumab does not seem to alter this risk. 122, 123 Trastuzumab has been shown to penetrate the blood-brain barrier (BBB) to a very limited extent, with cerebrospinal fluid (CSF) concentrations approximately two orders of magnitude lower than serum concentration, despite a possibly impaired BBB. 124, 125 Nonetheless, several retrospective studies have shown that trastuzumab is able to prolong survival in patients who develop CNSmetastases, 126 ,127 comparedwithcontrolgroups ofHer-2negativepatientsandHer2-positivepatients whodidnotreceivetrastuzumab. 123 Wholebrainradiation treatment (WBRT) is generally considered to bethestandardofcareforthissubsetofpatientsand isabletoimprovetheCSF:serumtrastuzumabconcentration ratio by approximately five-fold. 124 Since differentagentscanachieveobjectiveremissionsinthe CNS,bothaloneandincombinationwithWBRT(i.e. temozolomide, capecitabine, lapatinib, topotecan), 128 many oncologists believe that a reasonable strategy could be to continue trastuzumab in order to control metastases outside the brain and to administer active therapiestocontrolCNSdisease.Newapproachesin ordertodelivertrastuzumabdirectlytotheCNSare under investigation.
Use in Imaging
Trastuzumab has been evaluated as an imaging tool in the context of nuclear medicine techniques. In particular, the development of indium-111 ( 111 In)-labelled trastuzumab and its use in Single Photon Emission Computed Tomography (SPECT) have shown potential value for clinical staging of Her2-positive breast cancers in terms of identificationofnewtumourlesions,butwhenthemyocardial distribution of the drug was evaluated, the authors wherenotabletodemonstrateanypredictingability withregardtotrastuzumab-relatedcardiotoxicity. 129 In order to overcome the limited spatial resolution of 111 In-DTPA-trastuzumab SPECT imaging, trastuzumab has been successfully radiolabelled with Zirconium-89( 89 Zr) and its uptake has been detected by Positron Emission Tomography (PET), achieving a higher spatial resolution and a better signal-tonoise ratio.
130
InanotherapproachtheFragmentantigen-binding F(ab')2oftrastuzumabwaslabelledwithGallium-68 ( 68 Ga), and detected with PET. 131 Both the whole antibodies and the antibody fragments, which are characterized by a faster clearance, have allowed non-invasive imaging of the pharmacodynamics of anti-cancer agents as part of pre-clinical studies in animal models 132,133 but they are not currently used in clinical practice.
Resistance
Only 15 to 30% of Her2-positive metastatic breast cancers respond to trastuzumab administered as a single agent, whereas the response rate when used in combination with taxanes is approximately 60 to 70%.Thissuggeststhataproportionofpatientsare primarily resistant to trastuzumab. Moreover, virtually all patients with advanced disease treated with trastuzumabwillhaverecurrentdisease,indicatingan acquiredresistance.Furthermore,intheadjuvantsettingthereareasignificantproportionofpatientswho sufferfromrecurrentdiseasedespitehavingreceived trastuzumab.
These clinical observations have prompted several researchers to examine in depth the biological mechanismsoftrastuzumabresistance. 134 Two Her2 isoforms, the first lacking the extracellular domain (p95HER2) and the second lacking a small portion of the juxta-membrane extracellular domain (HER2∆16), were described to harbour enhanced transforming activity [135] [136] [137] and recent in vitroandclinicalworksshowthatthesevariantsare involved in trastuzumab resistance. 138, 139 Increased signalling from members of the ErbB family of receptorsandfromInsulin-likeGrowthFactorType1 Receptor(IGF-1R)hasbeenobservedbyMotoyama et al 66 andNathaetal 140 inthecontextoftrastuzumabresistant cells and these initial data have been confirmedbytherecentdemonstrationofaheterotrimeric (Her2/Her3/IGF-1R) complex which would disrupt effective binding of trastuzumab to Her2 and activateuniquedown-streamsignalling. 141 Activationof thePI3Kpathwayhasbeenshowntobeimportantin trastuzumabdownstreameffectsandcanberegulated byPhosphataseandTensinhomolog(PTEN).In vitro and clinical studies suggest that activation of this pathwayandlossofPTENfunctionmaycontribute to trastuzumab unresponsiveness. 142 The membraneassociated glycoprotein MUC4, which may hinder trastuzumab binding to its epitope on Her2, has also beenproposedasanadditionalmarkerofresistance. 143 Some of these pathways and mechanisms are currently being evaluated as potential therapeutic targets in pre-clinical and clinical studies. 
Use of trastuzumab beyond progression of disease
Since limited second-line options are currently available in the clinic for patients who experience disease progression after first-line trastuzumabcontaining therapies, many oncologists have been using trastuzumab following disease progression for several years, mostly in combination with variouschemotherapeuticagents.Thischoicewasbased ontrastuzumab'sknownchemo-sensitizingproperty and supported by data from a number of retrospective series. [146] [147] [148] Recently, a randomized study has assessedtheefficacyofcontinuationoftrastuzumab inassociationwithcapecitabine 149 andhasconfirmed the clinical benefit of this option, at least in terms of PFS. A second controlled study, which assessed theefficacyofcontinuedtrastuzumabinassociation with lapatinib versus lapatinib alone, demonstrated anadvantageforthecombinedanti-Her2therapy. 150 These observations, along with several in vitro experiments, 151 seemtosuggestthatinpatientswho loseclinicalresponsiveness,theanti-tumoureffectof trastuzumab is in part retained and can be exploited in thecontextofdifferentcombinationregimens.
Place in Therapy
Trastuzumabhasawidely-establishedroleintheroutine treatment of early and advanced Her2-positive breast cancer patients. In the adjuvant setting, trastuzumabiscommonlyadministeredforatotalduration ofoneyear,withvariationsregardingthetimingand schedule of administration (Table 1) . In metastatic patients, a combination therapy with chemotherapeuticagentsisusuallypreferred:inparticular,taxanes are the most extensively-studied partner drugs inthiscontext.However,combinationwithdifferent agents, including aromatase inhibitors, is feasible and effective. The pharmacodynamic and pharmacokinetic equivalence of the weekly and 3-weekly regimenallowsclinicianstochoosethemostconvenient schedule, taking into account patients' preference, associated chemotherapy regimen and hospital facilities.Furthermore,thesafetyandtolerabilityof thistreatmentallowaprolongedtreatmentinthevast majorityofcases.Besidestheintroductionoflapatinib intrastuzumab-resistantpatients,thedevelopmentof new drugs and combinations which can potentially refinethetreatmentofHer2-positive cancersisawide andexcitingfieldofinvestigation.
